Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2025.Dec.05

News

OBI-902 Receives Consecutive FDA Orphan Drug Designation
Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma

2025.Nov.16

News

OBI-902 has been granted by US FDA for Orphan Drug Designation for the treatment of Cholangiocarcinoma.

2025.Oct.21

News

OBI Volunteers Actively Participated in TBCA’s Pink October Event to Support Breast Cancer Awareness and Prevention

Read More

2025.Dec.05

Announcement

OBI receives US FDA Orphan Drug Designation for OBI-902 TROP2 ADC for the treatment of gastric cancer

2025.Nov.24

Announcement

Announcement of the Company’s record date of capital reduction, record date of share replacement, and related operational plan

2025.Nov.16

Announcement

OBI receives US FDA Orphan Drug Designation for OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2025 Investors' Meeting - Innovation in Action

Download PDF

Read More

2025 First Extraordinary General Shareholders’ Meeting

  • 2025.Oct.20 at 09:00 AM
  • Taipei Bioinnovation Park 1F Conference Room
Youtube

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact